Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Sell from Neutral at Goldman Sachs with analyst Jami Rubin saying pressure on key products combined with still-slow MD&D growth and continued strains on the consumer will leave the company with below average, long-term growth. 2. United Continental (UAL) downgraded to Market Perform at Raymond James with analyst Savanthi Syth saying an improvement in relative profitability versus legacy peers is likely to take longer than previously expected. 3. Ingersoll-Rand (IR) downgraded to Neutral from Overweight at JPMorgan with analyst C. Stephen Tusa saying he sees more relative upside and better risk/rewards elsewhere in the Electrical Equipment and Multi Industry sector. The analyst expects the company's solid execution to continue and raised his price target for the shares to $98 from $96. 4. L Brands (LB) downgraded to Market Perform from Outperform at Cowen with analyst Oliver Chen saying he sees risk to its comparable sales growth and margins if the company can not achieve elevated pricing. 5. Yahoo Japan (YAHOY) downgraded to Hold from Buy at Jefferies with analyst Hiroko Sato citing a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

JNJ Johnson & Johnson
$133.80

-1.42 (-1.05%)

09/20/17
GSCO
09/20/17
DOWNGRADE
Target $130
GSCO
Sell
Johnson & Johnson downgraded to Sell from Neutral at Goldman Sachs
Goldman analyst Jami Rubin downgraded Johnson & Johnson to Sell and increased its price target to $130 from $125 saying pressure on key products combined with still-slow MD&D growth and continued strains on the consumer will leave the company with below average, long-term growth. Rubin is forecasting Johnson & Johnson sales adjusted earnings CAGR of 5%-7% versus 5%-10% for the large cap pharma sector. As a result, the analyst views Johnson & Johnson's valuation as "stretched" on a relative value basis.
08/31/17
UBSW
08/31/17
NO CHANGE
Target $148
UBSW
Buy
Johnson & Johnson remain a top pick, says UBS
UBS analyst Matt Miksic met with Johnson & Johnson management and came away remaining confident in his conviction of his bullish view on the company. The analyst sees sustained Pharma growth, stable Med Device growth and an improving Consumer division. He identifies multiple drivers, including its pipeline and potential deal interest in Eye Care, Dental, Structural Heart and Neurology. Miksic reiterated his Buy rating and $148 price target on the stock, adding Johnson & Johnson remains a top pick.
08/14/17
BTIG
08/14/17
UPGRADE
Target $100
BTIG
Buy
Masimo upgraded to Buy, could be acquired by Johnson & Johnson, says BTIG
BTIG analyst Sean Lavin upgraded Masimo (MASI) to Buy from Neutral with a $100 price target saying he is more bullish on the Philips (PHG) agreement leading to increased revenue and margins, and the recent share pullback has provided a buying opportunity. Lavin said Masimo has been executing "superbly" and believes the Philips' relationship will drive acceptance of hemoglobin and Rainbow. Further, the analyst thinks Johnson & Johnson (JNJ) could be an acquirer of Masimo as it sells its products into the OR and ICU markets and would "massively" expand operating margins, and notes Philips may see the value of Masimo's products and make a bid.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $148
JPMS
Overweight
Johnson & Johnson price target raised ahead of ESC meeting at JPMorgan
JPMorgan analyst Michael Weinstein raised his price target for Johnson & Johnson shares to $148 from $140 ahead of the European Society of Cardiology beginning on August 26. The big event for J&J is the presentation of the COMPASS trial, investigating the use of Xarelto for the treatment of coronary or peripheral artery disease, Weinstein tells investors in a research note. His statistical analysis suggests a minimum 25% reduction in major adverse cardiac events, or MACE. This would make COMPASS a "landmark event in the treatment of CAD/PAD" and lead to Xarelto being adopted as the new standard of care in this greater than $5B indication, Weinstein writes. He recommends buying J&J shares ahead of the European Society of Cardiology meeting and keeps an Overweight rating on the name.
UAL United Continental
$58.01

0.47 (0.82%)

09/20/17
RAJA
09/20/17
DOWNGRADE
RAJA
Market Perform
United Continental downgraded to Market Perform at Raymond James
Raymond James analyst Savanthi Syth downgraded United Continental to Market Perform from Outperform saying an improvement in relative profitability versus legacy peers is likely to take longer than previously expected. He expects unit revenue and earnings underperformance to weigh on shares in the medium term and lowered estimates to reflect the aggressive pricing environment and negative impact from hurricane Harvey.
09/18/17
09/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Finish Line (FINL) downgraded to Underweight from Neutral at Piper Jaffray with analyst Erinn Murphy saying she sees further downside risk to estimates. 2. United Continental (UAL) downgraded to Neutral from Buy at Buckingham with the firm's analyst cutting his 2018 pre-tax earnings forecast by 20% and expects the multiple to contract further as consensus estimates are reset lower. 3. Brooks Automation (BRKS) downgraded to Hold from Buy at Needham with analyst Y. Edwin Mok citing valuation. 4. Wipro (WIT) downgraded to Sell from Neutral at Goldman Sachs with the firm saying earnings growth stays anemic while valuation is rich. 5. Taubman Centers (TCO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Richard Hill stating that while Taubman owns the highest quality portfolio of malls, its second quarter results showed its smaller portfolio may give it less negotiating leverage with retailers than peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/17
BUCK
09/18/17
DOWNGRADE
Target $65
BUCK
Neutral
United Continental downgraded to Neutral from Buy at Buckingham
Buckingham downgraded United Continental to Neutral and slashed its price target to $65 from $96 to reflect incremental weakness in Pacific bookings, concerns on its ability to successfully execute on domestic revenue, and concerns regarding the reacceleration of 50-seat RJ flying. The firm's analyst cut his 2018 pre-tax earnings forecast by 20% and expects the multiple to contract further as consensus estimates are reset lower.
09/15/17
09/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Equifax (EFX) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing news of a major hack on the company's data that could have lasting effects. 2. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz citing TNT issues following the cyber-attack in June that knocked out multiple systems. 3. Carnival (CCL) downgraded to Neutral from Outperform at Credit Suisse with analyst Tim Ramskil saying he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. 4. American Airlines (AAL), United Continental (UAL), and Spirit Airlines (SAVE) were downgraded to Neutral from Overweight at JPMorgan. 5. Acuity Brands (AYI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Richard Kwas saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IR Ingersoll-Rand
$88.85

-1.61 (-1.78%)

08/03/17
ARGS
08/03/17
NO CHANGE
ARGS
Ingersoll-Rand weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the recent weakness in Ingersoll-Rand has created a buying opportunity. The analyst expects the company to benefit from positive macro catalysts and its acquisitions going forward. He keeps a Buy rating on the shares.
07/27/17
UBSW
07/27/17
NO CHANGE
Target $97
UBSW
Buy
Ingersoll-Rand price target raised to $97 from $90 at UBS
UBS analyst Damian Karas raised his price target on Ingersoll-Rand to $97 from $90 following Q2 results. The analyst noted material prices may become a headwind but he said the climate outlook is intact as industrial growth and margins continue to improve. Karas reiterated his Buy rating on Ingersoll-Rand shares.
09/20/17
JPMS
09/20/17
DOWNGRADE
Target $98
JPMS
Neutral
Ingersoll-Rand downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst C. Stephen Tusa downgraded Ingersoll-Rand to Neutral saying he sees more relative upside and better risk/rewards elsewhere in the Electrical Equipment and Multi Industry sector. The analyst expects the company's solid execution to continue and raised his price target for the shares to $98 from $96.
07/27/17
STFL
07/27/17
NO CHANGE
STFL
Ingersoll-Rand weakness creates buying opportunity, says Stifel
Stifel analyst Robert McCarthy says that Ingersoll-Rand reported "solid" Q2 EPS. He blames the subsequent decline in its stock on "weaker than expected margins at Climate and soft Commercial HVAC bookings in the quarter." Calling both of those issues "largely transitory," he thinks that the company can generate low teen percentage EPS growth in the future. He recommends buying the stock on weakness.
LB L Brands
$37.40

-1.83 (-4.66%)

09/20/17
09/20/17
DOWNGRADE
Target $39

Market Perform
L Brands downgraded to Market Perform at Cowen
As previously reported, Cowen analyst Oliver Chen downgraded L Brands to Market Perform from Outperform as he sees risk to its comparable sales growth and margins if the company can not achieve elevated pricing. The analyst, who still believes the company has one of the best management teams in the retail sector and that its business trends should eventually improve, trimmed his price target on the stock to $39 from $40.
09/12/17
BERN
09/12/17
INITIATION
Target $57
BERN
Outperform
L Brands initiated with an Outperform at Bernstein
Bernstein analyst Jamie Merriman started L Brands with an Outperform rating and $57 price target saying he expects a rebound to better growth.
09/20/17
COWN
09/20/17
DOWNGRADE
COWN
Market Perform
L Brands downgraded to Market Perform from Outperform at Cowen
09/19/17
LEHM
09/19/17
INITIATION
Target $41
LEHM
Equal Weight
L Brands initiated with an Equal Weight at Barclays
Barclays analyst Chethan Mallela started L Brands with an Equal Weight rating and $41 price target. The analyst after the close initiated coverage of the U.S. Retail Softlines sector with a Neutral industry view.
YAHOY Yahoo Japan
$9.02

-0.03 (-0.33%)

02/07/17
JPMS
02/07/17
UPGRADE
JPMS
Overweight
Yahoo Japan upgraded to Overweight from Neutral at JPMorgan
06/28/17
JPMS
06/28/17
INITIATION
Target $65
JPMS
Overweight
Altaba initiated with an Overweight at JPMorgan
JPMorgan analyst Doug Anmuth started Altaba (AABA) with an Overweight rating and $65 price target. The analyst cites expected upside in Alibaba (BABA), the ability for Altaba to close its 31% valuation discount over time, and expected Yahoo Japan (YAHOY) upside for his bullish thesis.
09/20/17
JEFF
09/20/17
DOWNGRADE
JEFF
Hold
Yahoo Japan downgraded to Hold from Buy at Jefferies
Jefferies analyst Hiroko Sato downgraded Yahoo Japan to Hold citing a lack of catalysts. The analyst sees only single-digit sales growth in FY18.
09/01/17
MKMP
09/01/17
NO CHANGE
Target $76
MKMP
Buy
MKM ups Altaba price target to $76 on higher Alibaba outlook
MKM Partners analyst Rob Sanderson raised his price target for Altaba (AABA) shares to $76 from $62 to reflect a higher outlook for the value of the company's Alibaba (BABA) stake. His new sum-of-the-parts valuation embeds a 12-month price target for Alibaba of $220, current value for other assets and the full 40% tax liability. The pretax value of Altaba's assets is now $95 per share, Sanderson tells investors in a research note. He sees tax efficiencies on the stake, upside in the value of Yahoo Japan (YAHOY) and sale of patents in excess of fair value as potential upside scenarios for Altaba. The analyst keeps a Buy rating on the shares. Altaba closed yesterday down 8c to $64.08.

TODAY'S FREE FLY STORIES

02:40
12/12/17
12/12
02:40
12/12/17
02:40
General news
FX Update: Narrow ranges have prevailed »

FX Update: Narrow ranges…

01:55
12/12/17
12/12
01:55
12/12/17
01:55
General news
FX Action: USD-JPY has plied a narrow 14 pip range »

FX Action: USD-JPY has…

NAV

Navistar

$40.07

0.17 (0.43%)

20:13
12/11/17
12/11
20:13
12/11/17
20:13
Upgrade
Navistar rating change at Stifel »

Navistar upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

GBT

Global Blood Therapeutics

$44.78

-0.925 (-2.02%)

20:10
12/11/17
12/11
20:10
12/11/17
20:10
Conference/Events
Global Blood Therapeutics to hold an investor webcast »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VMW

VMware

$121.09

1.52 (1.27%)

19:55
12/11/17
12/11
19:55
12/11/17
19:55
Conference/Events
VMware management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 17

    Jan

MMC

Marsh & McLennan

$83.93

-0.2 (-0.24%)

19:52
12/11/17
12/11
19:52
12/11/17
19:52
Conference/Events
Marsh & McLennan management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BG

Bunge

$69.67

-0.12 (-0.17%)

19:48
12/11/17
12/11
19:48
12/11/17
19:48
Conference/Events
Bunge management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

COP

ConocoPhillips

$51.69

0.12 (0.23%)

19:42
12/11/17
12/11
19:42
12/11/17
19:42
Conference/Events
ConocoPhillips management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BL

BlackLine

$35.04

0.37 (1.07%)

19:36
12/11/17
12/11
19:36
12/11/17
19:36
Conference/Events
BlackLine management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

AGIO

Agios Pharmaceuticals

$61.42

0.45 (0.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SGEN

Seattle Genetics

$55.27

-3.995 (-6.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Seattle Genetics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 16

    Dec

TCBK

TriCo Bancshares

$41.34

-0.3 (-0.72%)

19:15
12/11/17
12/11
19:15
12/11/17
19:15
Hot Stocks
TriCo to acquire FNB in transaction valued at roughly $315.3M »

TriCo Bancshares and FNB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:53
12/11/17
12/11
18:53
12/11/17
18:53
Hot Stocks
Archrock Partners LP names Raymond Guba interim CFO of general partner »

Archrock Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROC

Archrock

$9.80

0.3 (3.16%)

, APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:49
12/11/17
12/11
18:49
12/11/17
18:49
Hot Stocks
Archrock names Raymond Guba Interim CFO »

Archrock announced that…

AROC

Archrock

$9.80

0.3 (3.16%)

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAV

Advantage Oil & Gas

$4.05

0.05 (1.25%)

18:33
12/11/17
12/11
18:33
12/11/17
18:33
Hot Stocks
Advantage Oil & Gas announces 2018 capital budget of $175M »

Advantage Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

18:22
12/11/17
12/11
18:22
12/11/17
18:22
Upgrade
Rosneft rating change at Goldman Sachs »

Rosneft upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$24.85

-1.11 (-4.28%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Piper sees 'another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$4.14

-0.03 (-0.72%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Hot Stocks
Fate Therapeutics reports Day 100 results from Phase 1 stage of PROTECT trial »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GM

General Motors

$41.67

-0.35 (-0.83%)

18:14
12/11/17
12/11
18:14
12/11/17
18:14
Periodicals
GM CEO: Cutting EV tax credit 'will have an impact' on sales, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

EDIT

Editas Medicine

$23.60

-1.36 (-5.45%)

18:02
12/11/17
12/11
18:02
12/11/17
18:02
Hot Stocks
Editas Medicine reports results from expanded CRISPR genome editing strategies »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$39.09

0.42 (1.09%)

18:00
12/11/17
12/11
18:00
12/11/17
18:00
Hot Stocks
First Mid-Illinois Bancshares to acquire First BancTrust Corp for $73.8M »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$120.42

0.5 (0.42%)

17:46
12/11/17
12/11
17:46
12/11/17
17:46
Initiation
Chevron initiated  »

Chevron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$13.13

0.67 (5.38%)

17:44
12/11/17
12/11
17:44
12/11/17
17:44
Initiation
Gulfport Energy initiated at Credit Suisse »

Gulfport Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$57.13

0.75 (1.33%)

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Initiation
EQT Corporation initiated at Credit Suisse »

EQT Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

, BITCOIN

Bitcoin

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Hot Stocks
SEC Chairman says no initial coin offerings have been registered »

Securities and Exchange…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.